New hope for patients with rare lung cancer transformation

NCT ID NCT07414927

Not yet recruiting Disease control Sponsor: Shanghai Best-Link Bioscience, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called BL0020 in 48 adults whose lung cancer has changed from one type (non-small cell) to another (small cell) after standard treatment. The drug is given by IV every three weeks. The goal is to see if it can shrink tumors and control the disease in people who have no other standard options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL0020 (a polymer-drug conjugate containing the chemotherapy agent SN-38)
What this could lead to: If successful, this could provide a new treatment option for patients with a rare and aggressive form of lung cancer that currently has no standard therapy.
What could go wrong: This is an early-phase trial with only 48 participants, so results may not apply broadly. The drug may cause side effects typical of chemotherapy, and it is not yet known if it will improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL CARCINOMA OF LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL CARCINOMA OF LUNG

Contacts and locations

Locations

Shanghai Chest Hospital

Shanghai, 200030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.